今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-020923 Act: 34 Size: 21 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-020920 Act: 34 Size: 34 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-020299 Act: 34 Size: 74 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-020300 Act: 34 Size: 75 KB 网页链接
$Trident(TDAC)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001213900-21-018775 Act: 34 Size: 4 MB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-016780 Act: 34 Size: 4 MB 网页链接
$Trident(TDAC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001213900-21-016773 Act: 34 Size: 4 MB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-012785 Act: 34 Size: 70 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-012786 Act: 34 Size: 70 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-010983 Act: 34 Size: 842 KB 网页链接